Drug intelligence / Profile preview

dkk1 multi-epitope vaccine

Development stage
Preclinical
Modality
Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular
01

Overview

A DNA-based vaccine designed to induce immunity against Dickkopf-1 (DKK1), a secreted inhibitor of the canonical Wnt signaling pathway that is upregulated in several bone-related pathologies (especially rheumatoid arthritis and multiple myeloma)[1][2][3][8]. The vaccine utilizes multiple B cell epitope fragments from DKK1, linked together in a synthetic gene construct, and is typically delivered via plasmid DNA for intramuscular immunization. This approach neutralizes DKK1 activity, leading to reduced bone erosion and anti-tumor effects in mouse models. The vaccine stimulates both humoral and cellular immune responses, including the production of neutralizing antibodies against DKK1 and DKK1-specific CD4+ and CD8+ T cells[1][2][3].

Other names
dkk1 multiepitope dna vaccinedkk-1 multiepitope dna vaccinedkk 1 multiepitope dna vaccinedickkopf-1 multi-epitope vaccinedickkopf1 multi-epitope vaccinedickkopf 1 multi-epitope vaccine
02

Targets

DKK1 (Dickkopf-related protein 1)MHC I (MHC class I})TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on dkk1 multi-epitope vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dkk1 multi-epitope vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call